Alphamab Oncology (SEHK: 9966)
Health Care · Biotechnology · CN
HK$7.36
-11.44% today · -46.8% 1Y
Alphamab Oncology (SEHK: 9966) operates in the Biotechnology industry within the Health Care sector. The company is valued at $907.71M and employs 515 people.
Over the last twelve months the share price has lost 46.8%, trading between 6.23 and 15.68.
Tweenvest scores Alphamab Oncology across four factors: quality 61/100, value 76/100. Its strongest factor is value.
9966 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $907.71M
- Revenue (TTM)
- $76.26M
- P/E
- —
- EPS
- -0.18
- Dividend yield
- —
- Beta (5Y)
- 0.55
- 52-week high
- HK$15.68
- 52-week low
- HK$6.23
- Avg volume (3M)
- —
- Shares outstanding
- 968.51M
- Employees
- 515
- Next earnings
- —
About Alphamab Oncology
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
- ISIN
- KYG0330A1013
- Founded
- 2008
- Listed since
- Dec 12, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
| Jade Biosciences, Inc.NasdaqCM: JBIO | $915.17M | $14.39 | +1.91% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $910.45M | $19.00 | -8.32% |
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | $884.95M | $10.52 | -3.49% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $883.46M | CN¥5.76 | +0.17% |
| Monte Rosa Therapeutics, Inc.NasdaqGS: GLUE | $878.73M | $10.30 | -0.19% |
Figures last refreshed Oct 11, 2026.